Эндогенные дигиталисподобные ингибиторы Na+/K+-ATФазы в патогенезе солечувствительной артериальной гипертензии
Аннотация
Более 40 лет назад было высказано предположение о том, что эндогенные дигиталиспособные ингибиторы Nа+/К+-АТФазы играют важную роль в патогенезе солечувствительных форм артериальной гипертензии. Показано, что дигиталисподобные факторы образуются с адаптивной целью вызвать натрийурез путем угнетения Nа+/К+-АТФазы в почечных канальцах. Чрезмерная продукция этих веществ, однако, приводит к угнетению Nа+/К+-АТФазы в гладкомышечных клетках сосудов, что усугубляет вазоконстрикцию. У млекопитающих описаны эндогенные ингибиторы Nа+/К+-АТФазы, относящиеся к классам карденолидов (эндогенный оуабаин) и буфадиенолидов (маринобуфагенин). При экспериментальной солечувствительной гипертензии эндогенный оуабаин в ЦНС, путем активации ренин-ангиотензиновой системы стимулирует адренокортикальную продукцию маринобуфагенина (МБГ), являющегося натрийуретиком и вазоконстриктором. Исследование роли эндогенных дигиталисподобных гормоном может открыть новые возможности фармакологической терапии артериальной гипертензии.
Об авторах
О. В. Федорова
Национальный институт здоровья
Россия
Россия
А. Я. Багров
Национальный институт здоровья
Россия
Россия
Список литературы
1. Folkow B. Physiological aspects of primary hypertension: Physiol Rev 1992: 62: 347-504.
2. Dahl L.K., Knudsen K.D., Iwai J. Humoral transmission of hypertension: Evidence from parabiosis. Circ Res 1969; 24: 21-33.
3. DeWardener H.E., Clarkson E.M. Concept of natriuretic hormone. Physiol Rev 1985; 65: 658-759.
4. Buckalew V.Mjr. Endogenous digitalis-like factors. An historical overview. Front Biosci 2005: 10: 2325-34.
5. Gruher K.A., Whilaker J.M., Buckalew V.M. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature 1980; 287: 743-5.
6. Blanstein M.P. Sodium ions, calcium ions, blood pressure regulation and hypertension: A reassessment and a hypothesis. Am J Physiol 1977: 232: 167-73.
7. Hamlyn J.M., Ringel R., Schaeffer J., Levinson P.D., Hamilton B.P., Kowarski A.A., Blanstein M.P.A circulating inhibitor of Na' К'-ATPase associated with essential hypertension. Nature 1982: 300: 650-2.
8. Hamlyn J.M., Blaustein M.P., Bova S., DuCharme D.W., Harris D.W., Mandel F., Mathews W.R., Ludens J.H. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci 1991: 88: 6259-63.
9. Hamlyn J.M., Manunta P. Ouabain digitalis-like factors and hypertension. J Hypertens 1992: 10 (7): 99-111.
10. Blanco G., Mercer R.W., Isozymes of the Na'/K' -ATPase: heterogeneity in structure, diversity in function. Am J Physiol 1988; 275; 633-50.
11. Ludens J.H., Clark M.A., Kolbasa K.P., Hamlyn J.M. Digitalis-like factor and ouabain-like compound in plasma of volume-expanded dogs. J Cardiovasc Pharmacol 1993; 22 (2): 38-41.
12. Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., French A.W., Anderson D.P. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume exf illusion in anesthetized dogs. Cardiovasc Res 1996; 3D 296-305.
13. Manunta P., Messaggio E., Ballabeni E., Sciarrone MRR. Lanzani C., Ferrandi M., Hamlyn J.M., Cusi D., Galletti F., Bianchi G. Salt Sensitivity Study Group of the Italian Society of hypertension. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 2001: 38: 198-203.
14. Takahashi H., Iyoda I., Takeda K., Okajima H., Sasaki S., Yoshimura M., Nakagawa M., Ijicbi H. Centrally-induced vasopressor responses to ouabain are augmented in spontaneously hypertensive rats. Clin Exp Hypertens 1984: А6: 1499-515.
15. Iyoda I., Takahashi H., Lee L.C., Okajima H., Inoue A., Sasaki S., Takeda K., Yoshimura M., Ijichi H. Cardiovascular and sympathetic responses to ouabain injected into the hypothalamus in rats, Cardiovasc Res 1986: 20: 294-8.
16. Takahashi H., Matsusowa M., Ikegaki I., Nishimura M., Yoshimura M., Yamada Y., Sano Y. Brain renin-angiotensin system and the hypothalamic, digitalis-like Na'/K'-ATPase inhibitor in rats. Clin Exp Hypertens 1988: A10: 1285-7.
17. Leenen F.H.H., Ruzicka M., Huang B.S. The brain and salt-sensitive hypertension. Curr Hypertens Rep 2002: 4: 129-35.
18. Huang B.S., Leenen F.H.H. Sympathoexcilatory and pressor responses to increased brain sodium and ouabain are mediated via brain.Weill. Am J Physiol 1990: 270: 275-80.
19. Huang P.S., Leenen F.H. Both brain angiotensin II and "ouabain" contribute to sympathoexcitation and hypertension in Dabl S rats on high salt intake. Hypertension 1998: 32: 1028-33.
20. Leenen F.H.H., Harmsen E., Yu H. Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt-salt-sensitive vs. salt-resistanl rats. Am J Physiol 1994; 267: 1969-20.
21. Wang H., Leenen F.H.H. Brain sodium channels and central sodium-induced increases in brain ouabain-like compound and blood pressure. J Hypertens 2003: 21: 1519-24.
22. Flier J.S., Maratos-Flier E., Pallota J.A., Mclsaac D. Endogenous digitalis-like activity in the plasma of the toad I info marinus. Nature 1979; 279: 341-3.
23. Flier J.S., Edwards M.W., Daly J.W., Myers C.W. Widespread occurrence in frogs and loads of skin compounds interacting with the ouabain site of Na'/K'-ATPase. Science 1980: 208: 503-5.
24. Lichtstein D., Gati I., Babila T., Katz U. Effect of salt acclimation on digitalis-like compounds in the toad. Biochim Biophys Acta 1991: 1073: 65-8.
25. Kieval R.S., Butler V.P., Derguini F., Bruening R.C., Rosen M.R. Cellular elec-trophysiologic effects of vertebrate digitalis-like substances. J Am Coll Cardiol 1988; 11: 637-43.
26. Goto A., Yamada K., Isbii M. Sugimoto T., Yoshioka M. Immunoreactivity of endogenous digitalis-like factors. Biochem Pharmacol 1991:41: 1261-3.
27. Panesar N.S. Bujalin radioimmunoassays: in search of the endogenous digitalis-like substance. J Immunoassay 1994; 15:371-91.
28. Oda M., Kurosawa M., Numazawa S., Tanaka S., Akizawa Т., Ito К., Maeda M., Yoshida T. Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunocasay for using a monoclonal antibody. Life Sci 2001: 68: 1107-17.
29. Lichtstein D., Gati I., Samuelov S., Berson D., Rosenman Y., Landau L., Deutsch J. Identification of digitalis-like compounds in human calaractons lenses. Eur J Biochem 1993: 216: 261-8.
30. Sich B., Kirch U., Tepel M., Zidek W., Schoner W. Pulse pressure correlates in humans with a proscillaridin-A immunoreactive compound. Hypertension 1996; 27: 1073-7.
31. Hilton P.J., White R.W., Lord G.A., Garner G.V., Gordon D.B., Hilton M.J., Forni L.G., McKinnon W., Ismail F.M., Keenan M., Jones K., Morden W.E. An inhibitor of the sodium pump obtained from human placenta. Lancet 1999: 348: 303-5.
32. McKinnon W., Lord G.A., Forni L.G., Hilton P.J. Circulating sodium pump inhibitors in five volume-expanded humans. J Hypertens 2003: 21: 2315-21.
33. Bagrov A.Y., Fedorova O.V., Roukoyatkina N.I., Ukbanova M.V., Zabko E.P. Digitalis-like and vasoconstrictor properties of endogenous digoxin-like factor from Bufo marinus toad. Eur J Pharmacol 1993; 234: 165-72.
34. Bagrov A.Y., Roukoyatkina N.I., Dmitrieva R.I., Pinaev A.G., Fedorova O.V. Effects of two endogenous digitalis-like factors, ouabain and marinobufagenin in isolated rat aorta. Eur J Pharmacol 1995; 274: 151-8.
35. Bagrov A.Y., Fedorova O.V.,.Austin J.L., Dmitrieva R.I.,Anderson D.E. Endogenous marinobufagenin-like immunoreactive factor and Na'/K'-ATPase inhibition during voluntary hypoventilation. Hypertension 1995; 26: 781-8.
36. Bagrov A.Y., Dmitrieva R.I., Fedorova O.V., Kazakov G.P., Roukoyatkina N.I. Shpen V.M Endogenous marinobufagenin-like immunoreactive substance: A possible endogenous Na'/K' -ATPase inhibitor with vasoconstrictor activity. Am J Hypertens 1996: 9: 982-90.
37. Fedorova O.V., Doris P.A., Bagrov A.Y. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exp Hypertens 1998: 20: 581-91.
38. Fedorova O.V., Anderson D.E., Lakatta E.G., Bagrov A.Y. Interaction of high sodium chloride intake and psychosocial stress on endogenous ligands of the sodium pump and blood pressure in normotensive rats. Am J Physiol 2001; 281: 352-8.
39. Lopatin D.A., Ailamazian E.K., Dmitrieva R.I., Shpen V.M., Fedorova O.V., Doris P.A., Bagror A.Y. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17: 1179-87.
40. Gonick H.C., Ding Y., Vaziri N.D., Bagrov A.Y., Fedorova O.V. Simultaneous measurement of marinobufagenin. ouabain and hypertension -associated protein in various disease states. Clin Exp Hypertens 1998; 20: 617-27.
41. Fridman A.L., Matveev S.A., Agalakova N.I., Fedorova O.V., Lakatta E.G., Bagrov A.Y. Marinobufagenin. an endogenous ligand of a Na'/K'-ATPase, is a marker of congestive heart failure severity. J Hypertens 2002: 20: 1189-94.
42. Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., Howald W.N., Hunter A.P., Kuznetsova E.A., Shpen V.M. Bufodienolide nature of endogenous inhibitor of Na/K-ATPase in the urine from patients with acute myocardial infarction. Hypertension 1998: 31: 1097-103.
43. Komiyama Y., Dong X.H., Nishimura N., Masaki H., Yoshika M., Masuda M., Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels inpatients with terminal renal failure. Clin Biochem 2005; 38: 36-45.
44. Bagrov A., Fedorova O.V. Effects of tiro putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na/K pump in human mesenteric arteries. J Hypertens 1998; 16: 1953-8.
45. Fedorova O.V., Bagrov A.Y. Inhibition of Na'/K'-ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different alpha-subunit isoforms. Am J Hypertens 1997; 10: 929-35.
46. Fedorova O.V., Lakatta E.G., Bagrov A.Y. Endogenous Na,K pump ligands are differentially regulated during acute NaCHoading of Dabl rats. Circulation 2000: 102: 3009-14.
47. Fedorova O.V., Talan M.L., Agalakova N.I., Lkatta E.G., Bagrov A.Y. An endogenous ligand of a, sodium pump, marinobufagenin. is a novel mediator of sodium chloride dependent hypertension. Circulation 2002: 105: 1122-7.
48. Fedorora O.V., Kolodkin N.I., Agalakora N.I., Lakatta E.G., Bagrov A.Y. Marinobufagenin, an endogenous sodium pump ligand. in hypertensive Dahl salt-sensitive rats. Hypertension 2001: 37 (2): 462-6.
49. de Simoue G., Devereux R.B., Camargo M.J., Wallerson D.C., Sealey J.E., Laragh J.H. Reduction of development of left ventricular hypertrophy insalt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996; 9; 216-22.
50. Yoneda H., Toriumi W., Ohmachi Y., Okumura F., Eujimura H., Nishiyama S. Involvement of angiotensin II in development of spontaneous nephrosis in Dabl salt-sensitive rats. Eur J Pharmacol 1998; 362: 213-9.
51. Tamura K., Chiba E., Yokoyama N., Sumida Y., Yahana M., Tamura N., Takasaki I., Takagi N., Ishii M., Horiuchi M., Umemura S. Renin-angiotensin system and fibroneclin gene expression in Dahl Iwai salt-sensitire and sail-resistant rats. J Hypertens 1999: l7: 81-9.
52. Kobori H., Nishiyama A., Ahe Y., Navar L.G. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003: 41: 592-7.
53. Boddi M., Poggesi L., Coppo M., Zarone M., Sacchi S., Tania С., Neri Serneri N.G. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 1998: 31:.836-42.
54. Dmitrieva R.I., Bagrov A.Y., Lalli E., Sassone-Corsi P., Stocco D., Doris P.A. Mammalian bufodienolide is synthesized from cholesterol in the adrenal cortex by a /lath/ray which is independent of cholesterol side-chain cleat 'age. Hypertension 2000; 36; 442-8.
55. Fedorova O.V., Agalakova N.I., Zhurarin I.A., Talan M.L., Lakatta E.G., Bagrov A.Y. Angiotensin II (ATII) mediated cross-talk between central and peripheral sodium pump inhibitors in NaCl loaded Dahl-S rats. J Hypertens 2004: 22 (2): 64.
56. Adair D., Hiushaw A., Russell G., Rose J., Veille J., Buckalew V. Effects of Fah digoxin-specific antibodies on mean arterial pressure in severe preeclampsia. Am J Hypertens 1997; 10: 11 A.
57. Goodlin R.C. Antidigoxin antibodies in eclampsia. New Engl J Med 1988; 318: 518-9.
58. Fedorova O.V., Kolodkin N.I., Agalakora N.I., Namikas A.R., Bzhelyansky A., St-Louis J., Lakatta E.G., Bagrov A.Y. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 2005: 23: 835-42.
59. Beckman J.A., Coldfine A.B., Gordon M.B. Garrett L.A., Creager M.A. Inhibition of protein kinase С beta prevents impaired endothelium-dependent vasodilation caused by hypoglycemia in humans. Circ Res 2002: 90: 107-11.
60. Fedorova O.V., Dorofeera N.A., Lopatin D.A., Lakatta E.G., Bagrov A.Y. Phosphor diacelate potentiales Na'/K' -ATPase inhibition by a putative endogenous ligand, marinobufagenin. Hypertension 2002: 39: 298-302.
61. Bagrov A.Y., Dorofeera N.A., Lopatin D.A., Fedorova O.V., Lakatta E.G., Droy-Lefaix M-T. Cicletanine reverses vasoconstriction induced by a putative endogenous Na/K ATPase ligand. Marinobufagenin, via protein kinase С dependent mechanism. J Hypertens. 2000; 18; 209-15.
62. Fedorova O.V., Talan M.L., Agalakova N.I., Droy-Lefaix M-T., Lakatta E.G., Bagrov A.Y. Reduction in myocardial PKC B, Na'/K'-ATP ase sensitivity to marinobufagenin and blood pressure in response to ciclelanine. Hypertension 2003: 41: 505-11.
63. Ferrari P., Ferrandi M., Tripodi G., Torielli L., Padoani G., Minotti E., Melloni P., Bianchi G. PST 2238: A new antihypertensive compound that modulates Na. K-ATPase in genetic hypertension. J Pharmacol Exp Ther 1999; 288: 1074-83.
64. Semplicini A., Serena L., Valle R., Ceolotto G., Felice M., Fontebasso A., Pessina A.C. Ouabain-inhibiting activity of aldosterone antagonists. Steroids. 1995; 60: 110-3.
Рецензия
Для цитирования:
Федорова О.В., Багров А.Я. Эндогенные дигиталисподобные ингибиторы Na+/K+-ATФазы в патогенезе солечувствительной артериальной гипертензии. Артериальная гипертензия. 2005;11(2):132-137.
For citation:
Fedorova O.V., Bagrov A.Y. Endogenous digitalis-like Nа+/К+-ATPase inhibitors in the pathogenesis of salt-sensitive arterial hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2005;11(2):132-137. (In Russ.)
Просмотров: 404
Послать статью по эл. почте 